Research on the potential mechanism of ginsenoside Rg3 against gastric cancer based on network pharmacology

Gastric cancer (GC) remains one of the most prevalent malignancies worldwide, particularly in East Asia. Despite advancements in treatment strategies, the prognosis for advanced GC patients remains unsatisfactory. Ginsenoside Rg3, a key bioactive component derived from Panax ginseng, has demonstrated significant antitumor effects in various cancers, including GC. This study systematically explores the potential mechanisms underlying the therapeutic effects of Ginsenoside Rg3, on GC, employing network pharmacology and molecular docking technologies. Key target genes and signaling pathways were identified, highlighting their critical roles in tumor cell proliferation, apoptosis, and metastasis. Molecular docking analyses revealed strong binding affinities between Ginsenoside Rg3, and crucial protein targets, supporting its direct interaction and functional modulation. The findings provide valuable insights into the molecular basis of Ginsenoside Rg3's anticancer activity and underscore its potential as a promising therapeutic candidate for GC. Future research and clinical studies are encouraged to validate these mechanisms and evaluate the clinical applicability of Ginsenoside Rg3.